Summary
Sun Pharma by obtaining this approval has added a small little jewel to its Kitty. Ophthalmic products are niche segments with few competitors. Margins are good and business is relatively stress free. I see a partner ship deal like Pfizer - Aurobindo / GSK - Reddy's in the very near future. All in all this approval will be a healthy addition to the bottom line
Analysis
Gaining ANDA approval is time consuming and expensive process.
Sun got rewarded to its sustained effort and has entered the much guarded Ophthalmic area.
Key advantages are good margin and less crowded market place.
What remains to be seen is Sun's ability to build successful business out of it.
This author consults with leading institutions through GLG
Analyses are solely the work of the authors and have not been edited or endorsed by GLG.
